Fu-Yue Zeng, Ph.D.

Fue-Yue Zeng profile picture

Fu-Yue Zeng, Ph.D.

Associate Director, Compound Management

Fu-Yue Zeng's Research Focus

High Throughput Functional Screening
Drug Discovery, Biochemistry

Dr. Zeng is Associate Director of High Throughput Screening and Compound Management at Sanford Burnham Prebys' Prebys Center. The center is equipped with state of the art ultra High Throughput Drug Screening (HTS) and lead discovery capabilities. His overall goal is to assist the center to execute high throughput screening projects, and to provide compound support for the Prebys Center team and principle investigators at the institute to enable the overall mission of the institute to translate basic research into therapies for patients.

Fu-Yue Zeng's Bio

Dr. Zeng has over 20 years of drug discovery and development experience, including 8 years with biotech companies. Before joining industry, Dr. Zeng was a staff scientist at National Institute of Health where he studied the structure and function of G-protein coupled receptors (GPCR). His work included the identification of key motifs, which activate muscarinic receptors, as well as the first discovery and characterization of muscarinic receptor dimerization.

In 1999, he took a team leader position at Arena Pharmaceuticals Inc. in San Diego, California, where he worked on developing novel GPCR screening assay platforms and drug discovery projects. In 2004, he transitioned to principal scientist at Novasite Pharmaceuticals Inc. in San Diego, where he continued on different GPCR drug discovery projects.

Dr. Zeng joined St. Jude Children Research Hospital at Memphis, Tennessee in 2007 where he helped establish a world-class automation high throughput screening system and managed a screening and drug discovery team. The team pursued projects in all classes of targets. He went on to join Sanford Burnham Prebys in 2009, where he is Associate Director of High Throughput Screening and Compound Management.

Dr. Zeng received his Ph.D. from the Faculty of Pharmacy of the Philips University of Marburg, Germany.


Career Highlights

2007-2009: Principal Scientist, Chemical Biology Department, St. Jude Children Research Hospital, Memphis, Tennessee
2004-2007: Principal Scientist, Novasite Pharmaceuticals Inc, San Diego, California
1999-2004: Team Leader, Arena Pharmaceuticals Inc, San Diego, California
1997-1999: Staff Scientist, NIDDK, NIH, Bethesda, Maryland

assay tray


High-throughput screening of compounds targeting RNA editing in Trypanosoma brucei: Novel molecular scaffolds with broad trypanocidal effects.

Rostamighadi M, Kamelshahroudi A, Mehta V, Zeng FY, Pass I, Chung TDY, Salavati R

Biochem Pharmacol 2024 Jan ;219:115937

Development of a Robust High-Throughput Screening Platform for Inhibitors of the Striatal-Enriched Tyrosine Phosphatase (STEP).

Lambert LJ, Grotegut S, Celeridad M, Gosalia P, Backer LJ, Bobkov AA, Salaniwal S, Chung TD, Zeng FY, Pass I, Lombroso PJ, Cosford ND, Tautz L

Int J Mol Sci 2021 Apr 23 ;22(9)

Serine-Threonine Kinase TAO3-Mediated Trafficking of Endosomes Containing the Invadopodia Scaffold TKS5α Promotes Cancer Invasion and Tumor Growth.

Iizuka S, Quintavalle M, Navarro JC, Gribbin KP, Ardecky RJ, Abelman MM, Ma CT, Sergienko E, Zeng FY, Pass I, Thomas GV, McWeeney SK, Hassig CA, Pinkerton AB, Courtneidge SA

Cancer Res 2021 Mar 15 ;81(6):1472-1485

Improving drug discovery using image-based multiparametric analysis of the epigenetic landscape.

Farhy C, Hariharan S, Ylanko J, Orozco L, Zeng FY, Pass I, Ugarte F, Forsberg EC, Huang CT, Andrews DW, Terskikh AV

Elife 2019 Oct 22 ;8

Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.

Feng Y, Sessions EH, Zhang F, Ban F, Placencio-Hickok V, Ma CT, Zeng FY, Pass I, Terry DB, Cadwell G, Bankston LA, Liddington RC, Chung TDY, Pinkerton AB, Sergienko E, Gleave M, Bhowmick NA, Jackson MR, Cherkasov A, Ronai ZA

Cancer Lett 2019 May 1 ;449:145-162

Cell-Based High-Throughput Luciferase Reporter Gene Assays for Identifying and Profiling Chemical Modulators of Endoplasmic Reticulum Signaling Protein, IRE1.

Rong J, Pass I, Diaz PW, Ngo TA, Sauer M, Magnuson G, Zeng FY, Hassig CA, Jackson MR, Cosford ND, Matsuzawa S, Reed JC

J Biomol Screen 2015 Dec ;20(10):1232-45

Show All Publications